Kirkland Represents Ribo on Series E1 Financing

Kirkland & Ellis advised Suzhou Ribo Life Science Co., Ltd. (Ribo), a clinical stage company developing innovative RNAi technologies and oligonucleotide therapeutics, on the successful completion of its $40 million Series E1 financing. The financing round investors included Panlin Capital, Trinity Innovation Fund and other existing and newly introduced investors. 

The Kirkland team was led by capital markets partner Mengyu Lu.